Literature DB >> 1133851

Genetics of susceptibility to plasmacytoma induction. I. BALB/cAnN (C), C57BL/6N (B6), C57BL/Ka (BK), (C times B6)F1, (C times BK)F1, and C times B recombinant-inbred strains.

M Potter, J G Pumphrey, D W Bailey.   

Abstract

Plasmacytomas were found in 58% of 373 BALB/cAnN (C) mice given three 0.5-ml doses of mineral oil (Bayol F or light mineral oil) or 2,6,10,14-tetramethylpentadecane (pristane) ip. The incidence of plasmacytomas in C57BL/6N (B6), C57BL/Ka (BK), (C times B6)F1 and (C times BK)F1 was 6.4, 0, 11.5, and 16.5%, respectively. The plasmacytomas occurred in old B6 mice, in contrast to their early appearance in strain C mice. The incidence of plasmacytomas in mineral oil-treated or pristane-treated C times B recombinant-inbred (Rl) strain mice was 28.3% in C times BD, 17.5% IN C times BE, 36.5% IN C times BG, 0% in C times BH, 2.9% in C times Bl, 48% in C times BJ, and 4.3% in C times BK. C times BD, C times BG, and C times BJ strains were considered susceptible to plascytoma induction by mineral oil or pristane; C times BE had a low susceptibility, and C times BH, C times Bl, and C times BK were resistant. The results suggested that there were only a few gene difference between C and B6 or BK that determined susceptibility or resistance to plasmacytoma induction, and that B6 and BK have at least one dominant resistance gene. The distribution pattern of susceptibility and resistance in the C times B Rl strains suggested the presence of a resistance gene on chromosome 9, linkage group II.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1133851     DOI: 10.1093/jnci/54.6.1413

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

Review 1.  Mouse chromosome 7.

Authors:  E M Rinchik; T Magnuson; B Holdener-Kenny; G Kelsey; A Bianchi; C J Conti; F Chartier; K A Brown; S D Brown; J Peters
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

Review 2.  Mouse chromosome 9.

Authors:  D M Kingsley
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

Review 3.  Mouse chromosome 9.

Authors:  D M Kingsley
Journal:  Mamm Genome       Date:  1991       Impact factor: 2.957

4.  IL-6 transgenic mouse model for extraosseous plasmacytoma.

Authors:  Alexander L Kovalchuk; Joong Su Kim; Sung Sup Park; Allen E Coleman; Jerrold M Ward; Herbert C Morse; Tadamitsu Kishimoto; Michael Potter; Siegfried Janz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

Review 5.  Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Authors:  Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

6.  Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis.

Authors:  B A Mock; M M Krall; J K Dosik
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

7.  Multiple genetic loci modify susceptibility to plasmacytoma-related morbidity in E(mu)-v-abl transgenic mice.

Authors:  R C Andrew Symons; Mark J Daly; Jane Fridlyand; Terence P Speed; Wendy D Cook; Steven Gerondakis; Alan W Harris; Simon J Foote
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-30       Impact factor: 11.205

8.  Friend erythroleukemia antigen. A viral antigen specified by spleen focus-forming virus and differentiation antigen controlled by the Fv-2 locus.

Authors:  R Risser
Journal:  J Exp Med       Date:  1979-05-01       Impact factor: 14.307

9.  Effects of 5-azacytidine on expression of endogenous retrovirus-related sequences in C3H 10T1/2 cells.

Authors:  W L Hsiao; S Gattoni-Celli; I B Weinstein
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

10.  A serum protein polymorphism determinant on chromosome 9 of Mus musculus.

Authors:  E M Eicher; B A Taylor; S C Leighton; J E Womack
Journal:  Mol Gen Genet       Date:  1980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.